GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Cyclically Adjusted PB Ratio

Oncolytics Biotech (Oncolytics Biotech) Cyclically Adjusted PB Ratio : 1.36 (As of Apr. 27, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Oncolytics Biotech's current share price is $1.09. Oncolytics Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.80. Oncolytics Biotech's Cyclically Adjusted PB Ratio for today is 1.36.

The historical rank and industry rank for Oncolytics Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:

ONCY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.48
Current: 1.38

During the past years, Oncolytics Biotech's highest Cyclically Adjusted PB Ratio was 2.48. The lowest was 0.00. And the median was 0.00.

ONCY's Cyclically Adjusted PB Ratio is ranked better than
55.23% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs ONCY: 1.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oncolytics Biotech's adjusted book value per share data for the three months ended in Dec. 2023 was $0.276. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.80 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncolytics Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Oncolytics Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Cyclically Adjusted PB Ratio Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.38 1.39 1.04 1.57 1.68

Oncolytics Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.26 2.88 2.62 1.68

Competitive Comparison of Oncolytics Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Oncolytics Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Cyclically Adjusted PB Ratio falls into.



Oncolytics Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oncolytics Biotech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.09/0.8
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Oncolytics Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.276/125.4675*125.4675
=0.276

Current CPI (Dec. 2023) = 125.4675.

Oncolytics Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.814 98.604 2.308
201406 1.641 99.473 2.070
201409 1.424 99.394 1.798
201412 1.217 98.367 1.552
201503 1.865 99.789 2.345
201506 1.967 100.500 2.456
201509 1.683 100.421 2.103
201512 1.447 99.947 1.816
201603 1.239 101.054 1.538
201606 1.152 102.002 1.417
201609 0.937 101.765 1.155
201612 0.628 101.449 0.777
201703 0.426 102.634 0.521
201706 0.732 103.029 0.891
201709 0.664 103.345 0.806
201712 0.435 103.345 0.528
201803 0.245 105.004 0.293
201806 0.506 105.557 0.601
201809 0.410 105.636 0.487
201812 0.265 105.399 0.315
201903 0.224 106.979 0.263
201906 0.140 107.690 0.163
201909 0.104 107.611 0.121
201912 -0.003 107.769 -0.003
202003 0.444 107.927 0.516
202006 0.434 108.401 0.502
202009 0.374 108.164 0.434
202012 0.419 108.559 0.484
202103 0.673 110.298 0.766
202106 0.692 111.720 0.777
202109 0.613 112.905 0.681
202112 0.512 113.774 0.565
202203 0.481 117.646 0.513
202206 0.415 120.806 0.431
202209 0.363 120.648 0.378
202212 0.318 120.964 0.330
202303 0.294 122.702 0.301
202306 0.255 124.203 0.258
202309 0.292 125.230 0.293
202312 0.276 125.468 0.276

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncolytics Biotech  (NAS:ONCY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oncolytics Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.

Oncolytics Biotech (Oncolytics Biotech) Headlines

From GuruFocus